Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain
antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with
COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still
unclear. The present study aims to evaluate the efficacy and safety of using convalescent
plasma for treating hospitalized patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Tânia Portella Costa
Collaborators:
Centro de Hematologia e Hemoterapia do Paraná - Hemepar Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná Science Valley Research Institute